keyword
MENU ▼
Read by QxMD icon Read
search

ramucirumab

keyword
https://www.readbyqxmd.com/read/29748017/antiangiogenic-therapy-for-patients-with-aggressive-or-refractory-advanced-non-small-cell-lung-cancer-in-the-second-line-setting
#1
REVIEW
Martin Reck, Marina Chiara Garassino, Martina Imbimbo, Frances A Shepherd, Mark A Socinski, Jin-Yuan Shih, Anne Tsao, Pablo Lee, Katherine B Winfree, Andreas Sashegyi, Rebecca Cheng, Rocio Varea, Benjamin Levy, Edward Garon
A majority of patients with advanced or metastatic non-small cell lung cancer (NSCLC) will experience disease progression after first-line therapy. Patients who have advanced NSCLC that is especially aggressive, which is defined as disease that rapidly progresses on first-line treatment or disease that is refractory to first-line treatment, have a critical unmet medical need. These patients have a poor prognosis in the second-line setting. Several studies have recently shown that treatment with an antiangiogenic therapy may benefit these patients...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29724300/evaluation-of-the-safety-of-ramucirumab-in-japanese-patients-with-advanced-gastric-cancer
#2
M Iwai, D Ito, H Asano, S Adachi, K Okada, M Kimura, E Usami, K Matsuo, T Yoshimura, H Teramachi
As a result of the RAINBOW trial, ramucirumab plus paclitaxel was established as a second-line treatment of advanced gastric cancer. Regarding the safety of ramucirumab plus paclitaxel in the Japanese, a subgroup analysis of the RAINBOW trial was conducted. The incidence of neutropenia was higher in Japanese patients. However, information is lacking concerning the safety of ramucirumab after marketing in Japanese patients. Therefore, the aim of this study was to evaluate the safety of ramucirumab in Japanese patients with advanced gastric cancer...
May 1, 2018: Die Pharmazie
https://www.readbyqxmd.com/read/29721850/exposure-response-relationship-for-ramucirumab-from-the-randomized-double-blind-phase-3-revel-trial-docetaxel-versus-docetaxel-plus-ramucirumab-in-second-line-treatment-of-metastatic-non-small-cell-lung-cancer
#3
Egbert F Smit, Edward B Garon, Martin Reck, Federico Cappuzzo, Paolo Bidoli, Roger B Cohen, Ling Gao, Lisa M O'Brien, Pablo Lee, Annamaria Zimmermann, David R Ferry, Allen S Melemed, Maurice Pérol
PURPOSE: Ramucirumab plus docetaxel improved survival in REVEL, a randomized phase 3 trial for patients with Stage IV non-small cell lung cancer after standard platinum-based chemotherapy. This exploratory analysis evaluated the exposure-response relationship of ramucirumab from REVEL. METHODS: Patients received ramucirumab (10 mg/kg) or placebo plus docetaxel (75 mg/m2 ) every 3 weeks. Pharmacokinetic samples were collected. A population pharmacokinetic analysis predicted ramucirumab minimum concentration after first-dose administration (Cmin,1 ) and average concentration at steady state (Cave,ss )...
May 2, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29713498/association-of-baseline-absolute-neutrophil-counts-and-survival-in-patients-with-metastatic-colorectal-cancer-treated-with-second-line-antiangiogenic-therapies-exploratory-analyses-of-the-raise-trial-and-validation-in-an-electronic-medical-record-data-set
#4
Axel Grothey, Takayuki Yoshino, Gyorgy Bodoky, Tudor Ciuleanu, Rocio Garcia-Carbonero, Pilar García-Alfonso, Eric Van Cutsem, Kei Muro, Daniel S Mytelka, Li Li, Olga Lipkovich, Yanzhi Hsu, Andreas Sashegyi, David Ferry, Federico Nasroulah, Josep Tabernero
Background: In the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously treated metastatic colorectal cancer versus patients treated with placebo+FOLFIRI but had a higher incidence of neutropaenia, leading to more chemotherapy dose modifications and discontinuations. Thus, we conducted an exploratory post-hoc analysis of RAISE and a retrospective, observational analysis of electronic medical record (EMR) data to determine and verify the association of neutropaenia, baseline absolute neutrophil count (ANC) and survival...
2018: ESMO Open
https://www.readbyqxmd.com/read/29674442/first-report-of-dramatic-tumor-responses-with-ramucirumab-and-paclitaxel-after-progression-on-pembrolizumab-in-two-cases-of-metastatic-gastroesophageal-adenocarcinoma
#5
Sakti Chakrabarti, Haidong Dong, Harshita R Paripati, Helen J Ross, Harry H Yoon
Checkpoint inhibitors targeted at programmed cell death-1 receptor (PD-1) and its ligand (PD-L1) can result in significant benefit to a small proportion of patients with cancer, including those with tumors of the stomach and gastroesophageal junction. These drugs are now approved for several solid tumors, including the recent accelerated approval of pembrolizumab for gastroesophageal adenocarcinomas in the third-line setting and beyond based on the KEYNOTE-059 phase II trial. Data are lacking on the efficacy of chemotherapy after progression on PD-1 blockade in metastatic gastroesophageal adenocarcinoma...
April 19, 2018: Oncologist
https://www.readbyqxmd.com/read/29674041/optimization-of-classification-and-regression-analysis-of-four-monoclonal-antibodies-from-raman-spectra-using-collaborative-machine-learning-approach
#6
Laetitia Minh Maï Le, Balázs Kégl, Alexandre Gramfort, Camille Marini, David Nguyen, Mehdi Cherti, Sana Tfaili, Ali Tfayli, Arlette Baillet-Guffroy, Patrice Prognon, Pierre Chaminade, Eric Caudron
The use of monoclonal antibodies (mAbs) constitutes one of the most important strategies to treat patients suffering from cancers such as hematological malignancies and solid tumors. These antibodies are prescribed by the physician and prepared by hospital pharmacists. An analytical control enables the quality of the preparations to be ensured. The aim of this study was to explore the development of a rapid analytical method for quality control. The method used four mAbs (Infliximab, Bevacizumab, Rituximab and Ramucirumab) at various concentrations and was based on recording Raman data and coupling them to a traditional chemometric and machine learning approach for data analysis...
July 1, 2018: Talanta
https://www.readbyqxmd.com/read/29670046/resistance-to-anti-angiogenic-therapy-in-cancer-alterations-to-anti-vegf-pathway
#7
REVIEW
Yoshiro Itatani, Kenji Kawada, Takamasa Yamamoto, Yoshiharu Sakai
Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular endothelial growth factor (VEGF) A, was approved for the first time as an anti-angiogenic drug for the treatment of metastatic colorectal cancer (CRC) by the Food and Drug Administration (FDA) in 2004. In addition, the other VEGF pathway inhibitors including small molecule tyrosine kinase inhibitors (sunitinib, sorafenib, and pazopanib), a soluble VEGF decoy receptor (aflibercept), and a humanized monoclonal antibody of VEGF receptor 2 (VEGFR2) (ramucirumab) have been approved for cancer therapy...
April 18, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29666801/current-therapeutic-landscape-for-advanced-gastroesophageal-cancers
#8
REVIEW
Anthony Lopez, Kazuto Harada, Dilsa Mizrak Kaya, Jaffer A Ajani
Treatment of advanced gastroesophageal cancers remains challenging for clinicians, patients, and caregivers alike. Despite considerable research, the therapeutic armamentarium is restricted and hardly personalized. In the first-line setting, trastuzumab with a fluoropyrimidine and platinum agent is the standard-of-care in patients with HER2-positive tumor. For the others, a platinum-based doublet (preferably with oxaliplatin) is recommended. Three-drug cytotoxic regimens should be reserved for exceptional cases where patients have good performance status...
February 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29650937/-an-elderly-case-of-recurrent-neuroendocrine-carcinoma-of-the-stomach-treated-with-ramucirumab
#9
Noriaki Koizumi, Hiroki Kobayashi, Tsuyoshi Takagi, Kanehisa Fukumoto
An 84-years-old man underwent total gastrectomy with D1 plus lymph node dissection in December 2015, and diagnosed as Stage III B neuroendocrine carcinoma of the stomach. An abdominal computed tomography revealed swollen paraaortic lymph nodes and left adrenal grand in May 2016. Since his serum level of CA19-9 was elevated, he was thus diagnosed as having recurrence, and was started chemotherapy with ramucirumab(RAM). After introduction of the chemotherapy, his serum level of CA19-9 was decreased gradually and metastatic foci were also decreased in size...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29582224/ramucirumab-as-second-line-therapy-in-metastatic-gastric-cancer-real-world-data-from-the-ramoss-study
#10
Maria Di Bartolomeo, Monica Niger, Giuseppe Tirino, Angelica Petrillo, Rosa Berenato, Maria Maddalena Laterza, Filippo Pietrantonio, Federica Morano, Maria Antista, Sara Lonardi, Lorenzo Fornaro, Stefano Tamberi, Elisa Giommoni, Alberto Zaniboni, Lorenza Rimassa, Gianluca Tomasello, Teodoro Sava, Massimiliano Spada, Tiziana Latiano, Alessandro Bittoni, Alessandro Bertolini, Ilaria Proserpio, Katia Bruna Bencardino, Francesco Graziano, Giordano Beretta, Salvatore Galdy, Jole Ventriglia, Simone Scagnoli, Andrea Spallanzani, Raffaella Longarini, Ferdinando De Vita
BACKGROUND: Ramucirumab-alone or combined with paclitaxel-represents one of the main options for patients failing first-line treatment for advanced gastric cancer. OBJECTIVE: The RAMoss study aimed to evaluate the safety and efficacy profile of ramucirumab in the "real-life setting". PATIENTS AND METHODS: Patients from 25 Italian hospitals started therapy consisting of ramucirumab 8 mg/kg i.v. d1,15q28 with or without paclitaxel 80 mg/m2 i...
March 27, 2018: Targeted Oncology
https://www.readbyqxmd.com/read/29547556/update-in-systemic-and-targeted-therapies-in-gastrointestinal-oncology
#11
Nelson S Yee
Progress has been made in the treatment of gastrointestinal cancers through advances in systemic therapies, surgical interventions, and radiation therapy. At the Multi-Disciplinary Patient Care in Gastrointestinal Oncology conference, the faculty members of the Penn State Health Milton S. Hershey Medical Center presented a variety of topics that focused on this sub-specialty. This conference paper highlights the new development in systemic treatment of various malignant diseases in the digestive system. Results of the recent clinical trials that investigated the clinical efficacy of pegylated hyaluronidase, napabucasin, and L-asparaginase in pancreatic carcinoma are presented...
March 16, 2018: Biomedicines
https://www.readbyqxmd.com/read/29522457/molecular-characterization-of-gastric-carcinoma-therapeutic-implications-for-biomarkers-and-targets
#12
REVIEW
Lionel Kankeu Fonkoua, Nelson S Yee
Palliative chemotherapy is the mainstay of treatment of advanced gastric carcinoma (GC). Monoclonal antibodies including trastuzumab, ramucirumab, and pembrolizumab have been shown to provide additional benefits. However, the clinical outcomes are often unpredictable and they can vary widely among patients. Currently, no biomarker is available for predicting treatment response in the individual patient except human epidermal growth factor receptor 2 (HER2) amplification and programmed death-ligand 1 (PD-L1) expression for effectiveness of trastuzumab and pembrolizumab, respectively...
March 9, 2018: Biomedicines
https://www.readbyqxmd.com/read/29508095/ramucirumab-for-the-treatment-of-metastatic-gastric-or-gastroesophageal-junction-adenocarcinoma-following-disease-progression-on-first-line-platinum-or-fluoropyrimidine-containing-combination-therapy-in-japanese-patients-a-phase-2-open-label-study
#13
Kensei Yamaguchi, Kazumasa Fujitani, Fumio Nagashima, Yasushi Omuro, Nozomu Machida, Tomohiro Nishina, Toshiko Koue, Mika Tsujimoto, Kaijiro Maeda, Taroh Satoh
BACKGROUND: Ramucirumab, a monoclonal antibody vascular endothelial growth factor receptor-2 antagonist, given as monotherapy improved survival in a global phase 3 study (REGARD) of patients with gastric cancer. However, REGARD did not include Japanese patients. This study evaluated the efficacy and safety of ramucirumab monotherapy in Japanese patients with advanced gastric cancer. METHODS: This multicenter, open-label, nonrandomized phase 2 study (Clinicaltrials...
March 5, 2018: Gastric Cancer
https://www.readbyqxmd.com/read/29455269/the-efficacy-and-safety-of-targeted-therapy-with-or-without-chemotherapy-in-advanced-gastric-cancer-treatment-a-network-meta-analysis-of-well-designed-randomized-controlled-trials
#14
REVIEW
Ting-Ting Zhao, Hao Xu, Hui-Mian Xu, Zhen-Ning Wang, Ying-Ying Xu, Yong-Xi Song, Song-Cheng Yin, Xing-Yu Liu, Zhi-Feng Miao
BACKGROUND: Advanced gastric cancer (AGC) is a severe malignant tumor associated with high mortality. Targeted therapy is an important approach for improving the therapeutic effects of AGC treatment. This study evaluates the efficacy and safety of targeted agents for AGC patients. METHODS: PubMed, EmBase, and the Cochrane Library were searched for double-blind randomized controlled trials (RCTs) of AGC treatments published prior to July 2017. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and severe adverse effects (AEs) were evaluated to determine the efficacy and safety of targeted agents...
May 2018: Gastric Cancer
https://www.readbyqxmd.com/read/29453759/systemic-treatment-of-patients-with-advanced-unresectable-hepatocellular-carcinoma-emergence-of-therapies
#15
REVIEW
Weijing Sun, Roniel Cabrera
To date, sorafenib, a multiple tyrosine kinase inhibitor, is the only systemic agent approved by the FDA in the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Several other tyrosine kinase-inhibiting agents have been investigated in the first-line setting, either alone (sunitinib, brivanib, linifanib, and lenvatinib) or in combination with sorafenib (erlotinib and doxorubicin) in phase 3 trials. However, none of these studies demonstrated an improvement in survival over sorafenib...
February 17, 2018: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/29427038/efficacy-and-tolerability-of-ramucirumab-monotherapy-or-in-combination-with-paclitaxel-in-gastric-cancer-patients-from-the-expanded-access-program-cohort-by-the-korean-cancer-study-group-kcsg
#16
Minkyu Jung, Min-Hee Ryu, Do Youn Oh, Myounghee Kang, Dae Young Zang, In Gyu Hwang, Keun-Wook Lee, Ki Hyang Kim, Byoung Yong Shim, Eun Kee Song, Sun Jin Sym, Hye Sook Han, Young Lee Park, Jin Soo Kim, Hyun Woo Lee, Moon Hee Lee, Dong-Hoe Koo, Hong Suk Song, Namsu Lee, Sung Hyun Yang, Dae Ro Choi, Young Seon Hong, Kyoung Eun Lee, Chi Hoon Maeng, Jin Ho Baek, Samyong Kim, Yeul Hong Kim, Sun Young Rha, Jae Yong Cho, Yoon-Koo Kang
BACKGROUND: Ramucirumab improves survival in gastric cancer patients. The efficacy and safety of ramucirumab outside of a clinical trial were evaluated using an expanded access program (EAP). METHODS: Advanced gastric cancer patients treated with ramucirumab in combination with paclitaxel or with ramucirumab monotherapy in a Korean EAP were evaluated. Baseline characteristics were assessed for progression-free survival (PFS) and overall survival (OS), and adverse events were evaluated according to the treatment regimen...
February 9, 2018: Gastric Cancer
https://www.readbyqxmd.com/read/29397460/ramucirumab-for-the-treatment-of-patients-with-gastric-or-gastroesophageal-junction-cancer-in-community-oncology-practices
#17
A Scott Paulson, Lisa M Hess, Astra M Liepa, Zhanglin Lin Cui, Kathleen M Aguilar, Jamyia Clark, William Schelman
BACKGROUND: Limited real-world research has investigated ramucirumab for the treatment of patients with gastric or gastroesophageal junction (GEJ) cancer. This study was designed to describe ramucirumab monotherapy or combination therapy use in a community oncology practice setting. METHODS: This was a retrospective observational cohort study to describe the treatment of adult patients with gastric or GEJ cancer who initiated ramucirumab treatment between 4/21/14 and 6/30/16 within the US Oncology Network...
February 3, 2018: Gastric Cancer
https://www.readbyqxmd.com/read/29394701/-experience-of-ramucirumab-plus-folfiri-as-second-line-treatment-for-metastatic-colorectal-cancer-in-our-hospital
#18
Shigeta Hagino, Takashi Miyata, Koya Sakamoto
We experienced 2 cases in which ramucirumab plus FOLFIRI as second-line treatment was beneficial. Case 1 was a 67-yearold man, underwent panitumumab plus mFOLFOX6 as first-line treatment for unresectable rectal cancer with ureteral invasion and multiple liver metastases, but the disease became worse at 9.3 months. We changed to ramucirumab plus FOLFIRI as second-line treatment. After 2 courses, a grade 3 febrile neutropenia was observed, but treatment was beneficial and continued administration for 9 months or more...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394687/-continued-chemotherapy-for-advanced-gastric-cancer-and-seven-year-survival-after-operation
#19
Ryohei Yukimoto, Kazuyuki Okada, Tomohira Takeoka, Nobuo Takiguchi, Shigeto Nakai, Shoko Honda, Aoi Okamoto, Akina Saito, Hiroshi Matsuno, Ken Konishi, Hideo Ota, Shigekazu Yokoyama, Mutsumi Fukunaga, Kenji Kobayashi
The patient was a 66-year-old man. Total abdominal gastrectomy and D2 dissection were performed for gastric cancer (cT3N0M0P0CYXH0, cStage II A). Pathological examination confirmed a diagnosis of Stage III C mucinous adenocarcinoma (pT4pN3pM0, pStage III C). He underwent adjuvant chemotherapy with TS-1(120mg/body). One year after adjuvant chemotherapy, anastomotic stricture was caused. Although it was not possible to point out recurrent lesions on the CT image, we strongly suspected that extrinsic compression around the anastomotic portion was due to peritoneal dissemination recurrence because of symptoms and marked tumor elevation...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394654/-case-report-of-long-term-survival-for-stage-iv-advanced-sigmoid-colon-cancer-with-para-aortic-nodes-by-r0-resection-and-chemotherapy
#20
Masaaki Akai, Shinya Otsuka, Yuichi Yasui, Kenta Isoda, Ryousuke Hamano, Naoyuki Tokunaga, Kenji Takahashi, Hideaki Miyaso, Yousuke Tsunemitsu, Kazuhide Iwakawa, Masaru Inagaki, Hiromi Iwagaki
The patient was a man in his early 30s. He underwent sigmoidectomy with D3+ #216 for advanced sigmoid colon cancer with metastatic para-aortic lymph nodes. The pathological diagnosis was colon cancer(S), type 2, moderately differentiated, pT4a(SE), pN3(19/33), pM1a(LYM), pStage IV , KRAS wild-type, EGFR(+). He received FOLFOX plus bevacizumab(Bmab) as adjuvant chemotherapy. One year postoperatively, he experienced recurrence as multiple lung metastases. FOLFIRI plus panitumumab, SOX plus Bmab, CapeOX, nivolumab and FOLFIRI plus ramucirumab were then administered...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
46644
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"